Lycera is a preclinical biopharmaceutical company that focuses on developing first-in-class drugs to treat immune disorders such as rheumatoid arthritis, lupus erythematosus, and inflammatory bowel disease. Their proprietary small molecules modulate a target central to cellular bioenergetics and the Th17 pathway. Lycera aims to provide first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents. Their drugs have potential for treating psoriasis, cancer, and other autoimmune diseases.